Non-Small Cell Lung Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

The role of brigatinib in crizotinib-resistant non-small cell lung cancer - Dove Medical Press



The role of brigatinib in crizotinib-resistant non-small cell lung cancer 
Dove Medical Press
Abstract: Despite the advances in new targeted therapies in ALK positive population, most patients progress under ALK inhibitors within first 2 years; being the brain the most frequent site of relapse. ALK mutations, in ~30% of patients, are the main ...

 


Levy Discusses Remaining Questions in NSCLC as Field Awaits Frontline Osimertinib Approval - Targeted Oncology



Targeted Oncology
 
Levy Discusses Remaining Questions in NSCLC as Field Awaits Frontline Osimertinib Approval 
Targeted Oncology
While the FDA approval of osimertinib (Tagrisso) for patients with EGFR T790M?positive non?small cell lung cancer (NSCLC) who progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy has made a significant impact in the field of lung cancer ...

 


Proton Therapy Not Better Than IMRT in Lung Cancer - Medscape



Medscape
 
Proton Therapy Not Better Than IMRT in Lung Cancer 
Medscape
Proton Therapy Not Better Than IMRT in Lung Cancer. Roxanne Nelson, RN, BSN. January 18, 2018. The first randomized trial to compare proton therapy with conventional radiotherapy has not found a difference in toxicity, which is the main claim for ...

 


First-line Keytruda plus chemotherapy improves OS, PFS in non-small cell lung cancer - Healio



Drug Discovery & Development
 
First-line Keytruda plus chemotherapy improves OS, PFS in non-small cell lung cancer 
Healio
In the phase 3 KEYNOTE-189 trial ? which included 614 patients with advanced or metastatic nonsquamous non-small cell lung cancer, regardless of PD-L1 expression, who had no EGFR or ALK mutations and had not previously received systemic therapy for ...
Merek's KEYTRUDA Improved Overall Survival in Patients with Non-small Cell Lung Cancer Drug Discovery & Development
Keytruda/chemo combo extends survival in NSCLC patients PharmaTimes
Frontline Pembrolizumab Combo Improves Survival in Phase III ... OncLive
StreetInsider.com  -Zacks.com  -Seeking Alpha 
all 14 news articles » 


FDA Expands Gilotrif Indication for Non?Small-Cell Lung Cancer - P&T Community



PharmaTimes
 
FDA Expands Gilotrif Indication for Non?Small-Cell Lung Cancer 
P&T Community
The FDA has approved a supplemental new drug application (sNDA) for afatinib (Gilotrif, Boehringer Ingelheim) for the first-line treatment of patients with metastatic non?small-cell lung cancer (NSCLC) whose tumors have nonresistant epidermal growth ...
FDA Approves Expanded Indication for Gilotrif in NSCLC Monthly Prescribing Reference
US expands scope of BI's lung cancer drug Gilotrif PharmaTimes
FDA Expands Indication of Afatinib to Include EGFR-Mutated Lung Cancer Specialty Pharmacy Times
The Pharma Letter 
all 6 news articles » 


Qiagen Gets FDA OK for Expanded Use of EGFR CDx for Lung Cancer Drug - GenomeWeb



Qiagen Gets FDA OK for Expanded Use of EGFR CDx for Lung Cancer Drug 
GenomeWeb
NEW YORK (GenomeWeb) ? Qiagen said today that the US Food and Drug Administration has extended the indications for use of its Therascreen EGFR RGQ PCR kit to guide the use of Boehringer Ingelheim's Gilotrif (afatanib) for first-line treatment of ...

and more » 


NICE shoots down Pfizer's Xalkori in ROS1-positive patients, inviting a CDF proposal instead - FiercePharma



FiercePharma
 
NICE shoots down Pfizer's Xalkori in ROS1-positive patients, inviting a CDF proposal instead 
FiercePharma
?Using crizotinib in the Cancer Drugs Fund would provide important data? that right now NICE feels is lacking in untreated patients, it wrote. NICE will also take public comments until Feb. 7, ahead of a second appraisal meeting on Feb. 21. Pfizer, for ...

 


Bunn Expands on Significance of Atezolizumab/Bevacizumab Regimen in NSCLC - OncLive



OncLive
 
Bunn Expands on Significance of Atezolizumab/Bevacizumab Regimen in NSCLC 
OncLive
Findings from the phase III IMpower150 trial presented at the 2017 ESMO Immuno-Oncology Congress demonstrated that treatment with the combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel delayed progression or ...

 


Poor Baseline LIPI Associated With Worse Outcomes for ICI Treatment in Patients With NSCLC - AJMC.com Managed Markets Network



Poor Baseline LIPI Associated With Worse Outcomes for ICI Treatment in Patients With NSCLC 
AJMC.com Managed Markets Network
The authors conducted a multicentric retrospective study of 466 patients with advanced NSCLC receiving treatment with PD-1/PD-L1 inhibitors. Patients from Gustave Roussy treated with PD-1/PD-L1 inhibitors between November 2012 and July 2016 were ...

 


Various Immunotherapy Combinations Continue to Be Explored in NSCLC - OncLive



OncLive
 
Various Immunotherapy Combinations Continue to Be Explored in NSCLC 
OncLive
?We are still searching for the right combinations including immunotherapy for NSCLC,? said Daniel E. Haggstrom, MD. ?We have proven efficacy as single agents and in combination with chemotherapy; however, as newer agents are improved, the landscape ...

and more »